在克罗恩氏病中治疗维多利祖马布的现实有效性和患者分层:一项多中心回顾性研究
Kang Chao1,2, Zhaopeng Huang1,2, Hongsheng Yang1,2
1Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
维多利祖马布 (VDZ) 对克罗恩病有效,在没有囊和低炎症的生物原始患者中,表现最好. 一个预测模型有助于识别可能通过VDZ治疗实现无类固醇缓解的患者.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在炎症性肠病 (IBD) 中选择合适的患者接受vedolizumab (VDZ) 治疗具有挑战性.
- 这项多中心,回顾性研究解决了评估现实世界VDZ有效性的需要.
- 这项研究旨在确定从VDZ治疗中获益最多的患者子组.
研究的目的:
- 评估在克罗恩氏病患者中维多利祖马布 (VDZ) 的实际有效性和安全性.
- 识别治疗成功的预测因素,并开发一个预测无类固醇缓解的诺莫图.
- 在临床实践中指导患者选择VDZ治疗.
主要方法:
- 对264名克罗恩病患者的回顾性分析,这些患者在三个专业中心接受VDZ治疗.
- 评估结果,包括无类固醇缓解,临床缓解和26周和52周的客观反应.
- 应用LASSO回归和多变量分析来识别预测因子;开发一个预测26周无类固醇缓解的诺米克图.
主要成果:
- 无类固醇缓解率在26周为46.6%,在52周为38.6%.
- 客观反应率在26周为41.5%,在52周为20.7%.
- 没有活跃囊和低基线炎症 (CDAI ≤220,CRP ≤10 mg/L) 的生物原始患者表现出显著更高的缓解率和更好的治疗延续率 (所有P <0.05).
结论:
- 维多利祖马布 (VDZ) 在治疗克罗恩病方面表现出有效性和良好的安全性.
- 那些生物素朴的患者,缺乏活跃的肠,并且具有较轻微的基线疾病活性,更有可能获得VDZ的成功结果.
- 开发的诺米图有效预测无类固醇缓解,有助于个性化治疗策略.
更多相关视频
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Ulcerative Colitis in IBD
